Anemia Management and Association of Race With Mortality and Hospitalization in a Large Not-for-Profit Dialysis Organization

American Journal of Kidney Diseases

Volumn 54, Issue 3, 2009, Pages 498-510

  Servilla, Karen S ^a,b,c   Singh, Ajay K ^d   Hunt, William C ^b   Harford, Antonia M ^c   Miskulin, Dana ^e   Meyer, Klemens B ^e   Bedrick, Edward J ^f   Rohrscheib, Mark R ^c   Tzamaloukas, Antonios H ^a   Johnson, H Keith ^g   Zager, Philip G ^b,c  

^a NEW MEXICO VA HEALTH CARE SYSTEM   (United States)

^b Dialysis Clinic Inc   (United States)

^c UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e TUFTS MEDICAL CENTER   (United States)

^f UNIVERSITY OF NEW MEXICO   (United States)

^g Dialysis Clinic Inc   (United States)

Author keywords

Epoetin; hemodialysis; hemoglobin; hospitalization; mortality

Indexed keywords

IRON; RECOMBINANT ERYTHROPOIETIN; SERUM ALBUMIN;

ADULT; AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MORTALITY; RACE DIFFERENCE; RISK FACTOR;

ADULT; AGED; ANEMIA; COHORT STUDIES; CONTINENTAL POPULATION GROUPS; DISEASE MANAGEMENT; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBINS; HOSPITALIZATION; HUMANS; KIDNEY FAILURE, CHRONIC; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 68849087722     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2009.05.007     Document Type: Article

References (47)

1. Mohini R. Clinical efficacy of recombinant human erythropoietin in hemodialysis patients. Semin Nephrol 9 (1989) 16-21
2. Pisoni R.L., Bragg-Gresham J.L., Young E.W., et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 44 (2004) 94-111
3. Eschbach J.W., Abdulhadi M.H., Browne J.K., et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 111 (1989) 992-1000
4. Li S., and Collins A.J. Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. Kidney Int 65 (2004) 622-633
5. Ofsthun N., Labrecque J., Lacson E., Keen M., and Lazarus J.M. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 63 (2003) 1908-1914
6. Rao M., and Pereira B.J. Optimal anemia management reduces cardiovascular morbidity, mortality, and costs in chronic kidney disease. Kidney Int 68 (2005) 1432-1438
7. Regidor D.L., Kopple J.D., Kovesdy C.P., et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agents and survival in hemodialysis patients. J Am Soc Nephrol 17 (2006) 1181-1191
8. Robinson B.M., Joffe M.M., Berns J.S., Pisoni R.L., Port F.K., and Feldman H.I. Anemia and mortality in hemodialysis patients: Accounting for morbidity and treatment variables updated over time. Kidney Int 68 (2005) 2323 -2230
9. Xia H., Ebben J., Ma J.Z., and Collins A.J. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 10 (1999) 1309-1316
10. Zhang Y., Thamer M., Stefanik K., Kaufman J., and Cotter D.J. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 44 (2004) 866-876
11. Besarab A., Bolton W.K., Browne J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 (1998) 584-590
12. Singh A.K., Szczech L., Tang K.L., et al., CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006) 2085-2098
13. Drueke T.B., Locatelli F., Clyne N., et al., CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 (2006) 2071-2084
14. van Manen J.G., van Dijk P.C., Stel V.S., et al. Confounding effect of comorbidity in survival studies in patients on renal replacement therapy. Nephrol Dial Transplant 22 (2007) 187-195
15. Adamson J.W. Hyporesponsiveness to erythropoiesis stimulating agents in chronic kidney disease: The many faces of inflammation. Adv Chronic Kidney Dis 16 (2009) 76-82
16. Ebben J.P., Gilbertson D.T., Foley R.N., and Collins A.J. Hemoglobin level variability: Associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 1 (2006) 1205-1210
17. Fishbane S., and Berns J.S. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 68 (2005) 1337-1343
18. Lacson Jr. E., Rogus J., Teng M., Lazarus J.M., and Hakim R.M. The association of race with erythropoietin dose in patients on long-term hemodialysis. Am J Kidney Dis 52 (2008) 1104-1114
19. Owen Jr. W.J. Racial differences in incidence, outcome, and quality of life for African-Americans on hemodialysis. Blood Purif 14 (1996) 278-285
20. Price D.A., and Owen Jr. W.J. African-Americans on maintenance dialysis: A review of racial differences in incidence, treatment, and survival. Adv Ren Replace Ther 4 (1997) 3-12
21. Robinson B.M., Joffe M.M., Pisoni R.L., Port F.K., and Feldman H.I. Revisiting survival differences by race and ethnicity among hemodialysis patients: The Dialysis Outcomes and Practice Patterns Study. J Am Soc Nephrol 17 (2006) 2910-2918
22. Sargent J.A., and Gotch F.A. Mathematic modeling of dialysis therapy. Kidney Int Suppl 18 (1980) S2-S10
23. Weiner D.E., Miskulin D.C., Seefeld K., et al. Reducing versus discontinuing erythropoietin at high hemoglobin levels. J Am Soc Nephrol 18 (2007) 3184-3191
24. Aronoff G.R., Bennett W.M., Blumenthal S., et al. Iron sucrose in hemodialysis patients: Safety of replacement and maintenance regimens. Kidney Int 66 (2004) 1193-1198
25. Fletes S., Lazarus J.M., Gage J., and Chertow G.M. Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis 37 (2001) 743-749
26. Horl W.H. Should we still use iron dextran in hemodialysis patients. Am J Kidney Dis 37 (2001) 859-861
27. Kelly P.J., and Lim L. Survival analysis for recurrent event data: An application to childhood infectious diseases. Stat Med 19 (2000) 13-33
28. Fink J.C., Hsu V.D., Zhan M., et al. Center effects in anemia management of dialysis patients. J Am Soc Nephrol 18 (2007) 646-653
29. Collins A.J., Kasiske B., Herzog C., et al. Excerpts from the United States Renal Data System 2005 Annual Data report. Am J Kidney Dis 45 suppl 1 (2005) S41-S56
30. Bradbury B.D., Wang O., Critchlow C.W., et al. Exploring relative mortality and epoetin alfa dose among hemodialysis patients. Am J Kidney Dis 51 (2008) 62-70
31. Kilpatrick R.D., Critchlow C.W., Fishbane S., et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 3 (2008) 1077-1083
32. Bologa R.M., Levine D.M., Parker T.S., et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 32 (1998) 107-114
33. Bradbury B.D., Critchlow C.W., Weir M.R., Stewart R., Krishnan M., and Hakim R.H. Impact of elevated C-reactive protein levels on erythropoiesis-stimulating agent (ES) dose and responsiveness in hemodialysis patients. Nephrol Dial Transplant 24 (2009) 919-925
34. Honda H., Qureshi A.R., Heimburger O., et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 47 (2006) 139-148
35. Menon V., Wang X., Greene T., et al. Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease. Am J Kidney Dis 42 (2003) 44-52
36. Owen Jr. W.J., Lew N.L., Liu Y., Lowrie E.G., and Lazarus J.M. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 329 (1993) 1001-1006
37. Feldman H., Joffe M., Robinson B., et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 15 (2004) 1623-1632
38. Kalantar-Zadeh K., Regidor D.L., McAllister C.J., Michael B., and Warnock D.G. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 16 (2005) 3070-3080
39. Streja E., Kovesdy C.P., Greenland S., et al. Erythropoietin, iron depletion, and relative thrombocytosis: A possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis 52 (2008) 727-736
40. Kalantar-Zadeh K., McAllister C.J., Lehn R.S., Liu E., and Kopple J.D. A low serum iron level is a predictor of poor outcome in hemodialysis patients. Am J Kidney Dis 43 (2004) 671-784
41. Collins A.J., Kasiske B., Herzog C., et al. Excerpts from the United States Renal Data System 2006 Annual Data Report. Am J Kidney Dis 49 (2007) A6-A296
42. Kaufman J.S. Racial differences in erythropoietin responsiveness. Am J Kidney Dis 52 (2008) 1035-1038
43. Beutler E., and West C. Hematologic differences between African-Americans and whites: The roles of iron deficiency and alpha-thalassemia on hemoglobin levels and mean corpuscular volume. Blood 106 (2005) 740-745
44. Robins J.M., Hernan M.A., and Rotnitzky A. Effect modification by time-varying covariates. Am J Epidemiol 166 (2007) 994-1002
45. Benson K., and Hartz A.J. A comparison of observational studies and randomized, controlled trials. N Engl J Med 342 (2000) 1878-1886
46. Concato J., Shah N., and Horwitz R.I. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 342 (2000) 1887-1892
47. McKee M., Britton A., Black N., McPherson K., Sanderson C., and Bain C. Methods in health services research. Interpreting the evidence: Choosing between randomised and non-randomised studies. BMJ 319 (1999) 312-315